Solventum Corporation (NYSE:SOLV) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Solventum Corporation (NYSE:SOLV) have earned a consensus recommendation of “Moderate Buy” from the twelve analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and eight have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $92.80.

A number of analysts have weighed in on SOLV shares. KeyCorp increased their target price on shares of Solventum from $93.00 to $102.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Piper Sandler upped their price objective on shares of Solventum from $92.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Weiss Ratings upgraded shares of Solventum from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. BMO Capital Markets assumed coverage on shares of Solventum in a research note on Wednesday, July 8th. They set a “market perform” rating and a $81.00 target price for the company. Finally, Mizuho set a $113.00 target price on shares of Solventum in a report on Thursday, August 6th.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Independent Franchise Partners LLP boosted its holdings in Solventum by 19.0% in the fourth quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company’s stock worth $1,216,785,000 after acquiring an additional 2,456,451 shares in the last quarter. Diamond Hill Capital Management LLC Investment Advisor acquired a new stake in Solventum in the second quarter valued at approximately $150,066,000. Norges Bank bought a new stake in shares of Solventum during the fourth quarter valued at approximately $147,467,000. Bank of New York Mellon Corp bought a new stake in shares of Solventum during the second quarter valued at approximately $61,460,000. Finally, Geode Capital Management LLC raised its position in shares of Solventum by 20.0% during the fourth quarter. Geode Capital Management LLC now owns 4,588,728 shares of the company’s stock worth $362,375,000 after purchasing an additional 763,308 shares during the period.

Solventum Stock Up 0.2%

Shares of NYSE:SOLV opened at $87.98 on Friday. The business has a fifty day simple moving average of $88.43 and a 200 day simple moving average of $78.43. Solventum has a 12-month low of $62.38 and a 12-month high of $94.16. The firm has a market cap of $14.98 billion, a P/E ratio of 10.76, a P/E/G ratio of 1.37 and a beta of 0.63. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.64. The company had revenue of $2.21 billion during the quarter, compared to analysts’ expectations of $2.15 billion. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The business’s quarterly revenue was up 2.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.69 earnings per share. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Analysts predict that Solventum will post 7.22 earnings per share for the current year.

About Solventum

Solventum Corporation (NYSE:SOLV) is a global healthcare company that develops products, technologies and services designed to support clinical care, healthcare operations and patient outcomes. The company serves healthcare providers, dental professionals, laboratories, manufacturers and other organizations.

Solventum’s portfolio includes medical and surgical products such as wound-care systems, surgical drapes, sterilization and infection-prevention solutions, and patient-monitoring or fixation products.